HC Wainwright Issues Positive Forecast for Eton Pharmaceuticals (NASDAQ:ETON) Stock Price

Eton Pharmaceuticals (NASDAQ:ETON) had its price objective boosted by analysts at HC Wainwright from $17.00 to $33.00 in a research report issued on Thursday,Briefing.com Automated Import reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 111.51% from the stock’s previous close.

ETON has been the topic of several other research reports. B. Riley initiated coverage on shares of Eton Pharmaceuticals in a research note on Friday, January 10th. They issued a “buy” rating and a $21.00 price objective on the stock. Craig Hallum increased their price target on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th.

Eton Pharmaceuticals Stock Performance

Eton Pharmaceuticals stock opened at $15.60 on Thursday. The firm has a market cap of $406.43 million, a PE ratio of -71.68 and a beta of 1.38. The firm’s 50 day moving average price is $12.59 and its two-hundred day moving average price is $8.06. Eton Pharmaceuticals has a twelve month low of $3.03 and a twelve month high of $15.71.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC grew its stake in Eton Pharmaceuticals by 63.8% in the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock valued at $350,000 after buying an additional 41,469 shares during the last quarter. Nantahala Capital Management LLC acquired a new position in Eton Pharmaceuticals in the 2nd quarter valued at $3,095,000. Stonepine Capital Management LLC acquired a new position in Eton Pharmaceuticals in the 2nd quarter valued at $362,000. Aristides Capital LLC acquired a new position in Eton Pharmaceuticals in the 2nd quarter valued at $658,000. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in Eton Pharmaceuticals by 86.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock valued at $390,000 after buying an additional 30,167 shares during the last quarter. Institutional investors and hedge funds own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.